Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Survey: Protected And Versatile Men's Razor - 2Robert Irwin on winning 'Dancing With the Stars' 10 years after sister Bindi: 'This was everything I dreamed it would be and so much more'
- 3Warship sunk by British fleet, remains of sailor found after 225 years
- 4Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
- 5Outer space conditions hamper sperm's ability to navigate toward an egg
- Ringleader of suspected human trafficking network arrested in Ethiopia
- Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- The pace of hiring just fell to the lowest since 2011, outside of the pandemic
- The biggest black hole breakthroughs of 2025
- The Best 15 Applications for Efficiency and Association
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- Fossil analysis changes what paleontologists know about how long T. rex took to grow full size
- 'The Secret Lives of Mormon Wives' Season 3 premieres tomorrow. Here's what you need to know to catch up.
